Advances in Medicine (AIM) 2026 | Conference News and Highlights | CIMS IN
  • Education
  •  Download App
  • Country
    singapore
    hong kong
    malaysia
    indonesia
    thailand
    philippines
    vietnam
    india

    australia
    korea
    new zealand
The CIMS logo.
  • Home
  • Find Drugs
  • Find Drug Company
  • Diseases
  • Medical News & Updates
The CIMS logo.
  • Home
  • Find Drugs
  • Find Drug Company
  • Diseases
  • Medical News & Updates
The CIMS logo.
Home
Find Drugs
Find Drug Company
Diseases
Medical News & Updates

Other Services
 Education
  Download App
Country
singapore
hong kong
malaysia
indonesia
thailand
philippines
vietnam
australia
korea
new zealand
Account
The CIMS logo.
  1. Medical News & Updates
  2. List of Conferences
  3. ...
    • Medical News & Updates
    • List of Conferences
  4. Advances in Medicine (AIM) 2026
Advances in Medicine (AIM) 2026

Advances in Medicine (AIM) 2026

Hong Kong 30 May 2026 - 31 May 2026

Imaging helps refine diagnosis and management in PsA
Imaging helps refine diagnosis and management in PsA
30 Jun 2026 byElaine Tan
Elaine Tan

Imaging complements clinical judgement in psoriatic arthritis (PsA) diagnosis and management, helping guide treatment to achieve remission or minimize disease progression, according to Professor Mikkel Østergaard of the University of Copenhagen, Denmark, who spoke at AIM 2026.

Imaging helps refine diagnosis and management in PsA
30 Jun 2026
Multimodal strategies needed to halt progression of MCI and Alzheimer’s disease
Multimodal strategies needed to halt progression of MCI and Alzheimer’s disease
04 Jun 2026 byKanas Chan
Kanas Chan

Early, long-term multimodal interventions are required to halt the progression of mild cognitive impairment (MCI) and Alzheimer’s disease, according to Professor Timothy Kwok of the Division of Geriatrics, Chinese University of Hong Kong (CUHK), who spoke at AIM 2026.

Multimodal strategies needed to halt progression of MCI and Alzheimer’s disease
04 Jun 2026
Donanemab delays Alzheimer's disease progression over 3 years
Donanemab delays Alzheimer's disease progression over 3 years
04 Jun 2026 byKanas Chan
Kanas Chan

Donanemab administered for a limited duration continues to slow clinical progression in patients with early symptomatic Alzheimer’s disease (AD) over 3 years, according to Professor Chaur-Jong Hu of the Department of Neurology, Taipei Medical University, who spoke at Advances in Medicine (AIM) 2026. 

Donanemab delays Alzheimer's disease progression over 3 years
04 Jun 2026
The CIMS logo.
  • Drugs
  • Find Drugs
  • Find Drug Company
  • CIMS Abbreviation Index
  • Diseases
  • Search Disease Information
  • Editorial Advisory Board
  • Medical News & Updates
  • Latest News & Updates
  • More Services
  • Education
  • Subscribe
  • About
  • MIMS Corporate
  • Terms of Use
  • Privacy Policy
  • Feedback
Connect with CIMS
A social media brand icon.A social media brand icon.A social media brand icon.A social media brand icon.A social media brand icon.
TUV Nord ISO 9001 certification logo
CIMS Specialty v3.13.1
Copyright © 2026 CIMS Pte Ltd. All rights reserved. PRD
CIMS Logo

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?
Something went wrong.